Jagsonpal Pharmaceuticals Ltd. (IN:JAGSNPHARM)
:JAGSNPHARM
Want to see IN:JAGSNPHARM full AI Analyst Report?
Top Page
Jagsonpal Pharmaceuticals Ltd.
(JAGSNPHARM)
Select Model
Select Model
Rating:75Outperform
Price Target:
₹237.00
▲(22.48% Upside)
Action:UpgradedDate:05/03/26
The score is driven mainly by strong financial performance (low leverage, solid margins, and strong recent cash conversion). Technicals add support via positive trend/momentum, but overbought readings raise near-term risk. Valuation is the key headwind due to a relatively high P/E and only modest yield.
Positive Factors
Low Leverage / Balance Sheet Strength
Extremely low leverage provides durable financial flexibility: the company can fund working capital, absorb cyclical downturns, pursue opportunistic M&A or invest in field force without raising costly debt. This conservatism reduces bankruptcy risk and supports long-term execution.
Negative Factors
Earnings Volatility
Year-to-year swings in net income reduce predictability of earnings and complicate capital allocation. Volatility can stem from episodic costs, pricing or demand shifts and undermines sustained return profiles, making long-term forecasting and valuation less certain.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Strength
Extremely low leverage provides durable financial flexibility: the company can fund working capital, absorb cyclical downturns, pursue opportunistic M&A or invest in field force without raising costly debt. This conservatism reduces bankruptcy risk and supports long-term execution.
Read all positive factors
Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹14.25B
Dividend Yield1.24%
Average Volume (3M)3.85K
Price to Earnings (P/E)37.1
Beta (1Y)0.99
Revenue Growth6.89%
EPS Growth-23.34%
CountryIN
Employees1,025
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding67,139,150
10 Day Avg. Volume3,534
30 Day Avg. Volume3,854
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)4.53
Price to Sales (P/S)4.35
P/FCF Ratio26.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and c...
How the Company Makes Money
Jagsonpal Pharmaceuticals primarily makes money by selling pharmaceutical formulations under its own brands. Revenue is generated from: (1) domestic sales of branded prescription products to the Indian market, typically supplied via a network of s...
Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
87
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.83B | 2.87B | 2.69B | 2.09B | 2.37B | 2.18B |
| Gross Profit | 1.80B | 1.83B | 1.72B | 652.59M | 1.44B | 1.28B |
| EBITDA | 862.81M | 679.90M | 510.71M | 323.46M | 363.96M | 284.53M |
| Net Income | 619.42M | 430.82M | 553.61M | 224.63M | 267.21M | 188.55M |
Balance Sheet | ||||||
| Total Assets | 2.99B | 3.17B | 2.78B | 2.17B | 1.95B | 1.68B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 1.06B | 1.29B | 1.48B | 1.15B | 472.77M |
| Total Debt | 88.36M | 81.65M | 92.39M | 89.41M | 60.01M | 52.47M |
| Total Liabilities | 461.88M | 405.05M | 383.10M | 296.76M | 360.56M | 375.99M |
| Stockholders Equity | 2.53B | 2.76B | 2.40B | 1.87B | 1.59B | 1.31B |
Cash Flow | ||||||
| Free Cash Flow | 245.77M | 466.64M | 549.52M | 349.18M | 463.37M | 51.31M |
| Operating Cash Flow | 246.75M | 468.12M | 553.00M | 351.66M | 466.54M | 55.98M |
| Investing Cash Flow | -82.07M | -356.49M | -451.47M | -245.48M | -576.71M | -257.79M |
| Financing Cash Flow | -148.90M | -121.49M | -116.98M | -89.11M | -4.57M | -175.52M |
Jagsonpal Pharmaceuticals Ltd. Technical Analysis
Positive
193.50
Price Trends
180.19
Positive
186.54
Positive
210.81
Negative
Market Momentum
4.12
Negative
61.24
Neutral
65.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Positive. The current price of 193.5 is above the 20-day moving average (MA) of 187.92, above the 50-day MA of 180.19, and below the 200-day MA of 210.81, indicating a neutral trend. The MACD of 4.12 indicates Negative momentum. The RSI at 61.24 is Neutral, neither overbought nor oversold. The STOCH value of 65.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JAGSNPHARM.
Jagsonpal Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹13.08B | 10.01 | ― | ― | 7.99% | 119.03% | |
78 Outperform | ₹12.84B | 8.47 | ― | 0.37% | 9.10% | -1.72% | |
75 Outperform | ₹14.25B | 37.13 | ― | 1.24% | 6.89% | -23.34% | |
71 Outperform | ₹14.32B | 22.21 | ― | ― | 35.49% | 67.03% | |
69 Neutral | ₹12.96B | 17.72 | ― | ― | 28.33% | 76.13% | |
56 Neutral | ₹11.79B | 18.86 | ― | ― | 32.95% | -10.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
212.25
-35.29
-14.26%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
135.95
60.04
79.09%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
641.25
78.66
13.98%
IN:SAKAR
Sakar Healthcare Ltd
652.50
372.15
132.74%
IN:SYNCOMF
Syncom Formulation (India) Ltd.
13.79
-2.67
-16.22%
IN:VENUSREM
Venus Remedies Limited
978.75
670.30
217.31%
Jagsonpal Pharmaceuticals Ltd. Corporate Events
Jagsonpal Pharmaceuticals Shareholders Clear ₹40 Crore Equity Buyback
Apr 27, 2026
Jagsonpal Pharmaceuticals has announced that its shareholders have approved a special resolution to buy back up to 1.6 million fully paid equity shares with a face value of ₹2 each at a price of ₹250 per share, for a total outlay not e...
Jagsonpal Pharma Wins Shareholder Nod for Rs 40 Crore Share Buyback
Apr 27, 2026
Jagsonpal Pharmaceuticals Ltd. has received shareholder approval for its proposed buyback of up to 1.6 million equity shares at Rs 250 per share, aggregating up to Rs 40 crore. The move is positioned as a key step in the company’s strategy t...
Jagsonpal Pharmaceuticals Allots 176,900 Shares Under ESOP 2022
Apr 13, 2026
Jagsonpal Pharmaceuticals has allotted 176,900 equity shares with a face value of Rs. 2 each under its Employee Stock Option Plan, 2022, to eligible employees following the exercise of vested options. The new shares, issued at various exercise pri...
Jagsonpal Pharma Discloses Rs 4.82 Crore Tax Demand, Plans Appeal
Mar 13, 2026
Jagsonpal Pharmaceuticals Ltd. has disclosed that it received an income-tax assessment order for assessment year 2024-25 from the Income Tax Department’s Faceless Assessment Unit, leading to a tax demand of Rs. 4.82 crore arising from disall...
Jagsonpal Pharma Grants 1.15 Million Stock Options Under ESOP 2022
Mar 9, 2026
Jagsonpal Pharmaceuticals Ltd. has approved the grant of 1,152,500 employee stock options under its 2022 Employee Stock Option Plan at an exercise price of Rs 139 per option, each convertible into equity shares of Rs 2. The options will vest in fo...
Jagsonpal Pharmaceuticals Allots ESOP Shares, Ups Paid-Up Capital
Mar 9, 2026
Jagsonpal Pharmaceuticals has allotted 71,800 equity shares of Rs. 2 each to eligible employees under its Employee Stock Option Plan 2022, following the exercise of vested options. The newly issued shares, priced at an exercise rate of Rs. 94 with...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.